| Name | Title | Contact Details |
|---|---|---|
James Fink |
Director of Facilities, EHandS and Security | Profile |
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class. Company leadership has a deep history and knowledge of cardiovascular drug development and is supported by a world-class team of scientific advisors. The company will soon begin enrolling MAT9001 in a confirmatory head-to-head PK/PD study vs Vascepa, after having shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels in a previous study, with data expected in Q42020. In addition, the Company is developing MAT2203, an oral, encochleated formulation of Amphotericin B, to treat serious invasive fungal infections. The drug is based on Matinas` proprietary lipid nano-crystal (“LNC”) platform technology which can help solve complex challenges relating to the safe and effective delivery of potent medicines, potentially making them more targeted, less toxic and orally bioavailable.
PSI is a leading full-service global Contract Research Organization whose key strength is predictable patient enrollment across multiple therapeutic areas. PSI is known in the industry as a CRO focused on ‘on-time project delivery. This is achieved through investing substantial effort and MD resources into performing quality feasibility assessments that provide an accurate predictor of study timelines. PSIs global reach allows us to run clinical trials across multiple continents, in 50+ countries around the world. PSIs reputation is that of a no-nonsense CRO focused on timely patient enrollment and project delivery. An exceptionally high repeat and referral business rates alongside low staff turnover are indicative of our commitment to be the best CRO in the world as measured by our clients and our employees. http://www.psi-cro.com
At Krystal Biotech, Inc., our mission is to make a meaningful difference in the lives of underserved patient populations suffering from debilitating skin diseases. We work to accomplish this goal through scientific innovation and operational excellence, believing that `nature operates in the shortest way possible`.
New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy – pioneering novel therapeutic strategies to address unmet medical needs. We are creating a new target set for drug discovery and development, and advancing innovative paradigms to treat a broad set of illnesses that are either neglected or inadequately addressed today. Our growing team is driven to transform fundamental discoveries on autophagy into promising therapeutic medicines.
Trait Biosciences Inc. is a leading biotechnology research organization providing proprietary technology to enable safer, lower cost, predictable, and superior quality cannabinoid products. With a world-class team of scientists and PhDs from more than 20 countries collaborating in our state-of-the-art Los Alamos laboratory, Trait Biosciences researchers are unlocking new breakthroughs in cannabinoid science. Trait Biosciences offers transformative technologies that create water-soluble cannabinoids, increase cannabinoid production, protect the plants from disease, tailor the production of cannabinoids and that can assure zero THC for hemp.